Does Stem Cell Stocks Explode Higher on NIH Announcement (Indie Research)?
According to numerous reports, the Obama administration approved the first 13 human embryonic stem cell lines for use by federally funded researchers. National Institute of Health director Francis Collins said, “This is the first down payment on what is going to be a much longer list,” and another 96 lines have been submitted to the NIH for review. The Stem Cell Stocks Index is up by 13% on the news, with select players jumping by 20% or more. The Index is now outperforming the S&P 500 by nearly 20% over the last month. Opexa Therapeutics (NASDAQ: OPXA – News) is leading the rally with a 40% leap. The stock remains well off its highs for the year as hype surrounding the company’s deal with Novartis (NYSE: NVS – News) cooled off. StemCells (NASDAQ: STEM – News) is up by over 20%, while Aastrom Biosciences (NASDAQ: ASTM – News) and Geron (NASDAQ: GERN – News) both also tack on double-digit percentage gains. As of this writing, the Stem Cell Stocks Index has jumped into tickerspy’s top-10
Related Questions
- Does UCSF separately account for research using HESC not on the NIH Human Embryonic Stem Cell Registry ("non-registry HESC") as opposed to Federally funded research?
- What are the NIH guidelines for embryonic stem cell research which will receive the recently approved federal funding?
- What research is the NIH involved in to further human embryonic stem cell research?
